Abstract
The molecular underpinnings associated to first episode psychosis (FEP) remains to be elucidated, but compelling evidence supported an association of FEP with blood alterations in biomarkers related to immune system, growth factors and metabolism regulators. Many of these studies have not been already confirmed in larger samples or have not considered the FEP diagnostic subgroups. In order to identify biochemical signatures of FEP, the serum levels of the growth factors BDNF and VEGF, the immune regulators IL-1RA, IL-6, IL-10 and IL-17, RANTES/CCL5, MIP-1b/CCL4, IL-8 and the metabolic regulators C-peptide, ghrelin, GIP, GLP-1, glucagon, insulin, leptin, PAI-1, resistin and visfatin were analysed in 260 subjects collected in the GET UP project. The results indicated an increase of MIP-1b/CCL4, VEGF, IL-6 and PAI-1, while IL-17, ghrelin, glucagon and GLP-1 were decreased in the whole sample of FEP patients (p < 0.01 for all markers except for PAI-1 p < 0.05). No differences were evidenced for these markers among the diagnostic groups that constitute the FEP sample, whereas IL-8 is increased only in patients with a diagnosis of affective psychosis. The principal component analysis (PCA) and variable importance analysis (VIA) indicated that MIP-1b/CCL4, ghrelin, glucagon, VEGF and GLP-1 were the variables mostly altered in FEP patients. On the contrary, none of the analysed markers nor a combination of them can discriminate between FEP diagnostic subgroups. These data evidence a profile of immune and metabolic alterations in FEP patients, providing new information on the molecular mechanism associated to the psychosis onset for the development of preventive strategies and innovative treatment targets.
| Original language | English |
|---|---|
| Pages (from-to) | 315-324 |
| Number of pages | 10 |
| Journal | Brain, Behavior, and Immunity |
| Volume | 70 |
| DOIs | |
| Publication status | Published - May 1 2018 |
Fingerprint
Keywords
- Cytokines and chemokines
- FEP
- Ghrelin
- GLP-1
- Glucagon
- IL-8
- Metabolic markers
- MIP-1b/CCL4
- VEGF
ASJC Scopus subject areas
- Immunology
- Endocrine and Autonomic Systems
- Behavioral Neuroscience
Cite this
Immune and metabolic alterations in first episode psychosis (FEP) patients. / the GET UP Group.
In: Brain, Behavior, and Immunity, Vol. 70, 01.05.2018, p. 315-324.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immune and metabolic alterations in first episode psychosis (FEP) patients
AU - the GET UP Group
AU - Bocchio-Chiavetto, Luisella
AU - Zanardini, Roberta
AU - Tosato, Sarah
AU - Ventriglia, Mariacarla
AU - Ferrari, Clarissa
AU - Bonetto, Chiara
AU - Lasalvia, Antonio
AU - Giubilini, Franco
AU - Fioritti, Angelo
AU - Pileggi, Francesca
AU - Pratelli, Michela
AU - Pavanati, Michele
AU - Favaro, Angela
AU - De Girolamo, Giovanni
AU - Frisoni, Giovanni Battista
AU - Ruggeri, Mirella
AU - Gennarelli, Massimo
PY - 2018/5/1
Y1 - 2018/5/1
N2 - The molecular underpinnings associated to first episode psychosis (FEP) remains to be elucidated, but compelling evidence supported an association of FEP with blood alterations in biomarkers related to immune system, growth factors and metabolism regulators. Many of these studies have not been already confirmed in larger samples or have not considered the FEP diagnostic subgroups. In order to identify biochemical signatures of FEP, the serum levels of the growth factors BDNF and VEGF, the immune regulators IL-1RA, IL-6, IL-10 and IL-17, RANTES/CCL5, MIP-1b/CCL4, IL-8 and the metabolic regulators C-peptide, ghrelin, GIP, GLP-1, glucagon, insulin, leptin, PAI-1, resistin and visfatin were analysed in 260 subjects collected in the GET UP project. The results indicated an increase of MIP-1b/CCL4, VEGF, IL-6 and PAI-1, while IL-17, ghrelin, glucagon and GLP-1 were decreased in the whole sample of FEP patients (p < 0.01 for all markers except for PAI-1 p < 0.05). No differences were evidenced for these markers among the diagnostic groups that constitute the FEP sample, whereas IL-8 is increased only in patients with a diagnosis of affective psychosis. The principal component analysis (PCA) and variable importance analysis (VIA) indicated that MIP-1b/CCL4, ghrelin, glucagon, VEGF and GLP-1 were the variables mostly altered in FEP patients. On the contrary, none of the analysed markers nor a combination of them can discriminate between FEP diagnostic subgroups. These data evidence a profile of immune and metabolic alterations in FEP patients, providing new information on the molecular mechanism associated to the psychosis onset for the development of preventive strategies and innovative treatment targets.
AB - The molecular underpinnings associated to first episode psychosis (FEP) remains to be elucidated, but compelling evidence supported an association of FEP with blood alterations in biomarkers related to immune system, growth factors and metabolism regulators. Many of these studies have not been already confirmed in larger samples or have not considered the FEP diagnostic subgroups. In order to identify biochemical signatures of FEP, the serum levels of the growth factors BDNF and VEGF, the immune regulators IL-1RA, IL-6, IL-10 and IL-17, RANTES/CCL5, MIP-1b/CCL4, IL-8 and the metabolic regulators C-peptide, ghrelin, GIP, GLP-1, glucagon, insulin, leptin, PAI-1, resistin and visfatin were analysed in 260 subjects collected in the GET UP project. The results indicated an increase of MIP-1b/CCL4, VEGF, IL-6 and PAI-1, while IL-17, ghrelin, glucagon and GLP-1 were decreased in the whole sample of FEP patients (p < 0.01 for all markers except for PAI-1 p < 0.05). No differences were evidenced for these markers among the diagnostic groups that constitute the FEP sample, whereas IL-8 is increased only in patients with a diagnosis of affective psychosis. The principal component analysis (PCA) and variable importance analysis (VIA) indicated that MIP-1b/CCL4, ghrelin, glucagon, VEGF and GLP-1 were the variables mostly altered in FEP patients. On the contrary, none of the analysed markers nor a combination of them can discriminate between FEP diagnostic subgroups. These data evidence a profile of immune and metabolic alterations in FEP patients, providing new information on the molecular mechanism associated to the psychosis onset for the development of preventive strategies and innovative treatment targets.
KW - Cytokines and chemokines
KW - FEP
KW - Ghrelin
KW - GLP-1
KW - Glucagon
KW - IL-8
KW - Metabolic markers
KW - MIP-1b/CCL4
KW - VEGF
UR - http://www.scopus.com/inward/record.url?scp=85044128008&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044128008&partnerID=8YFLogxK
U2 - 10.1016/j.bbi.2018.03.013
DO - 10.1016/j.bbi.2018.03.013
M3 - Article
AN - SCOPUS:85044128008
VL - 70
SP - 315
EP - 324
JO - Brain, Behavior, and Immunity
JF - Brain, Behavior, and Immunity
SN - 0889-1591
ER -